1. Home
  2. GPCR vs MDXG Comparison

GPCR vs MDXG Comparison

Compare GPCR & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GPCR
  • MDXG
  • Stock Information
  • Founded
  • GPCR 2016
  • MDXG 2006
  • Country
  • GPCR United States
  • MDXG United States
  • Employees
  • GPCR N/A
  • MDXG N/A
  • Industry
  • GPCR
  • MDXG Biotechnology: Pharmaceutical Preparations
  • Sector
  • GPCR
  • MDXG Health Care
  • Exchange
  • GPCR Nasdaq
  • MDXG Nasdaq
  • Market Cap
  • GPCR 1.1B
  • MDXG 1.1B
  • IPO Year
  • GPCR 2023
  • MDXG N/A
  • Fundamental
  • Price
  • GPCR $20.91
  • MDXG $6.94
  • Analyst Decision
  • GPCR Strong Buy
  • MDXG Buy
  • Analyst Count
  • GPCR 9
  • MDXG 1
  • Target Price
  • GPCR $75.63
  • MDXG $12.00
  • AVG Volume (30 Days)
  • GPCR 1.1M
  • MDXG 416.4K
  • Earning Date
  • GPCR 08-06-2025
  • MDXG 10-29-2025
  • Dividend Yield
  • GPCR N/A
  • MDXG N/A
  • EPS Growth
  • GPCR N/A
  • MDXG N/A
  • EPS
  • GPCR N/A
  • MDXG 0.21
  • Revenue
  • GPCR N/A
  • MDXG $363,774,000.00
  • Revenue This Year
  • GPCR N/A
  • MDXG $12.68
  • Revenue Next Year
  • GPCR N/A
  • MDXG $8.18
  • P/E Ratio
  • GPCR N/A
  • MDXG $33.02
  • Revenue Growth
  • GPCR N/A
  • MDXG 6.85
  • 52 Week Low
  • GPCR $13.22
  • MDXG $5.47
  • 52 Week High
  • GPCR $45.37
  • MDXG $10.14
  • Technical
  • Relative Strength Index (RSI)
  • GPCR 58.61
  • MDXG 46.16
  • Support Level
  • GPCR $18.49
  • MDXG $6.81
  • Resistance Level
  • GPCR $22.25
  • MDXG $7.14
  • Average True Range (ATR)
  • GPCR 1.16
  • MDXG 0.19
  • MACD
  • GPCR 0.15
  • MDXG -0.04
  • Stochastic Oscillator
  • GPCR 66.38
  • MDXG 26.53

About GPCR Structure Therapeutics Inc.

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.

About MDXG MiMedx Group Inc

MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.

Share on Social Networks: